Tetrahydrocannabivarin

This first-of-its-kind phase 2 grant will expedite the commercialization of cannabinoid ingredient production via precision fermentation. The funding aims to develop cost-effective active pharmaceutical ingredients for treating conditions such as appetite suppression, obesity, inflammation, and diabetes. Cellibre, established in 2019 by a team of biomanufacturing innovators, is dedicated to creating a sustainable manufacturing company that utilizes biological processes as production catalysts. “Every cell on Earth functions like a tiny factory, capable of being engineered as a new way to produce chemicals and ingredients in a better, cheaper, and more sustainable way," said Cellibre CEO Ben Chiarelli. "Cellibre harnesses the world’s most elegant manufacturing technology, nature, by moving cellular assembly lines found in natural systems into microorganisms like yeast to create proprietary molecular factories. By feeding these cells nutrients, they produce pure, natural ingredients or chemicals, reducing the need to disrupt ecosystems – creating a revolution in sustainable manufacturing.” Cellibre secures $2 million NIH grant for sustainable cannabinoid production The grant will support the production of high-demand, non-euphoric cannabinoids such as tetrahydrocannabivarin (THCV) and cannabigerol (CBG). THCV is promising for appetite suppression and obesity management, while CBG is being studied for antibacterial properties and potential treatments for cancer and inflammatory diseases. Cellibre’s technology reduces cannabinoid production costs by over ten-fold compared to traditional agricultural methods. Additionally, the environmental impact of growing plants for cannabinoid production is comparable to the greenhouse gas footprint of 15 million cars annually. Cellibre’s approach significantly lowers land, water, and energy use while improving the quality and consistency of these ingredients. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Cannabinoids have significant therapeutic benefits, but manufacturing these ingredients through legacy agriculture is riddled with challenges,” said Cellibre’s Chief Technology Officer, Dr. Spiros Kambourakis. “Our precision fermentation platform solves these problems by using biology to produce high-quality, lower-cost, more sustainable cultured cannabinoids – in essence deploying nature to combat climate change, improve supply chain resilience, and improve human wellness.” Cellibre’s platforms have already shown economic and quality advantages over traditional supply chains. The award will accelerate these advances as Cellibre moves from research and development to full commercialization, focusing on therapeutically relevant cannabinoids. Precision fermentation: The future of cost-effective pharmaceutical ingredients Cellibre’s precision fermentation 'cell factory platform' drastically reduces the greenhouse gas footprint associated with agricultural and petrochemical-based supply chains for various plant-based compounds. The technology ensures a consistent, scalable supply of pharmaceutical-grade ingredients, free from the variability and impurities of agricultural-based production. Beyond cannabinoids, Cellibre’s platform also includes key bioactives for clean beauty and wellness, such as resveratrol, naringenin, bakuchiol, and other functional ingredients. “Biology is the future of manufacturing,” Kambourakis stated. “By moving production from fields to fermentation, we can create products faster, at lower costs, and with higher quality, all while protecting our natural ecosystems.” Innovative bio-manufacturing reduces environmental impact and production costs With the global cannabinoid isolate market projected to surpass $34 billion by 2030 and over 400 active clinical trials in progress, Cellibre’s technologies are crucial for ensuring patient safety and access. Cellibre is a manufacturing technology company that employs an organism-agnostic approach to turn cells into specialized, sustainable factories for large-scale production of globally significant products. The company’s scientific team has led programs from ideation to commercialization, pioneering breakthroughs in energy, ingredients, medicines, and more. Initially, Cellibre focuses on enabling the production of pharmaceutical-grade natural products and bioactives, eliminating the need for agriculture and revolutionizing the sourcing, production, and consumption of these ingredients. Cellibre was founded in 2019 and is headquartered in San Diego, California.

Launches Natural Natural™ ingredient brand to raise consumer awareness of naturally-derived rare cannabinoids PORTLAND, Ore., Feb. 27, 2024 /PRNewswire/ -- Cannabis genetics company Phylos®, along with People Science, a direct-to-consumer scientific research and technology company, has conducted an IRB-approved, double-blind clinical research study on the effects of rare cannabinoid tetrahydrocannabivarin (THCV). Results of the study found that Natural Natural™ THCV by Phylos significantly increased energy, activity, motivation, and well-being compared to placebo, without the fatigue and munchies associated with THC consumption. "This study signifies a pivotal moment for the cannabis industry in understanding the effect of THCV in combination with THC," according to Alisha Holloway, PhD, Chief Scientific Officer at Phylos. "The Natural Natural THCV study allows us to leverage our exceptional plants in the advancement of targeted cannabis products, and to chart new territories in understanding the efficacy of natural cannabinoids." Research Results Research participants ingested unmedicated placebo gummies, THC-only gummies, and gummies infused with extract from Get Sh!t Done™ (GSD), a THCV-dominant plant bred by Phylos. The GSD gummies included distillate from the GSD plant with a roughly 2:1 ratio of THCV:THC. Detailed methodology can be found here. The study's core findings include: 20% more participants felt energized after consuming the GSD gummy compared to placebo. 40% more participants reported enjoying their daily activities after consuming the GSD gummy compared to placebo. Participants who consumed the THC-only gummy reported a 50% increase in hunger when taking full doses. Participants who consumed the GSD gummy did not report a statistically significant increase in hunger compared to placebo. Participants who consumed the THC-only gummy reported feeling fatigue three times more than the GSD group. Participants who consumed the GSD gummy reported significantly less fatigue than placebo. Both GSD and THC-only gummies increased activity, exercise performance, motivation, and well-being compared to placebo. Natural Natural™ Brand Launch Phylos announces Natural Natural, the consumer-facing ingredient brand commercializing the company's patented, naturally-derived rare cannabinoid genetics. "Consumers are seeking and deserve access to natural, plant-based wellness products that are backed by science," said Phylos Chief Commercial Officer Whitney Conroy. "Natural Natural is partnering with the industry's top growers, extractors, and brands to ensure customers know the products they purchase are made with the highest quality ingredients with proven effects." Brand partners include some of the industry's top-rated consumer brands including: Yada Yada, Camino, Lost Farms, Heavy Hitters, Kanha, Airgraft, and Garden Society in California; SHRED and Trailblazer in Canada; HiDays in Arizona; Tunnel Vision and Ozone in Illinois, Massachusetts, and New Jersey; Good Day in Maryland; reV in Michigan; Kites and Buddies in Oregon, and Moonlit Cannabis in Washington. Wholesale partners include Pacific Dutch Group and LEEF (CA); Ascend Wellness (IL, MA, NJ); The Pharm (AZ); Common Citizen (MI); Curio Wellness (MD); Schwazze (CO); Buddies (Oregon), with expansion plans into other states and countries in 2024. About Phylos Phylos is a cannabis genetics company that empowers growers of all sizes to produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seed lines that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary, patent-pending technology to provide partners with unparalleled rare cannabinoid genetics. It creates natural, safe, and effective ingredients under its Natural Natural brand utilizing its cultivation, extraction, and formulation expertise. Natural Natural THCV varieties power a high-quality supply chain of naturally derived THCV. About People Science Founded and led by pioneers of decentralized clinical trials, People Science is a technology-enabled clinical research organization with a mission to empower humanity with the tools and knowledge of science and medicine to improve ourselves, our communities, and our world. People Science is building a new people-forward clinical research infrastructure to support the evolution, knowledge, and understanding of alternative, complex, and complementary medicines. The People Science proprietary technology, Chloe (Consumer Health Learning & Organizing Ecosystem), is a consumer-friendly mobile app on the frontend, and a modular and configurable clinical research data management tool on the backend. The platform empowers individuals to answer the question, "Which alternative medicines work best for me?" while making scaled clinical evidence generation easier and more affordable for consumer brands, manufacturers, biotech and biopharma, and academic researchers. Learn more at People Science. Infographic and photos available upon request at Beth Graham, 904-214-6769, 373607@email4pr.com